Nuvation Bio, Inc. (NUVB)
3.99
-0.07
(-1.72%)
USD |
NYSE |
Nov 13, 16:00
3.98
-0.01
(-0.25%)
Pre-Market: 19:59
Nuvation Bio Enterprise Value : 1.213B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 1.213B |
| November 12, 2026 | 1.238B |
| November 11, 2026 | 1.319B |
| November 10, 2026 | 1.287B |
| November 09, 2026 | 1.340B |
| November 06, 2026 | 1.273B |
| November 05, 2026 | 1.284B |
| November 04, 2026 | 1.474B |
| November 03, 2026 | 1.460B |
| November 02, 2026 | 1.425B |
| October 30, 2026 | 1.485B |
| October 29, 2026 | 1.488B |
| October 28, 2026 | 1.425B |
| October 27, 2026 | 1.411B |
| October 26, 2026 | 1.396B |
| October 23, 2026 | 1.418B |
| October 22, 2026 | 1.463B |
| October 21, 2026 | 1.516B |
| October 20, 2026 | 1.488B |
| October 19, 2026 | 1.386B |
| October 16, 2026 | 1.375B |
| October 15, 2026 | 1.481B |
| October 14, 2026 | 1.456B |
| October 13, 2026 | 1.471B |
| October 12, 2026 | 1.534B |
| Date | Value |
|---|---|
| October 09, 2026 | 1.569B |
| October 08, 2026 | 1.552B |
| October 07, 2026 | 1.520B |
| October 06, 2026 | 1.527B |
| October 05, 2026 | 1.552B |
| October 02, 2026 | 1.619B |
| October 01, 2026 | 1.767B |
| September 30, 2026 | 1.781B |
| September 29, 2026 | 1.721B |
| September 28, 2026 | 1.714B |
| September 25, 2026 | 1.763B |
| September 24, 2026 | 1.760B |
| September 23, 2026 | 1.753B |
| September 22, 2026 | 1.889B |
| September 21, 2026 | 1.879B |
| September 18, 2026 | 1.802B |
| September 17, 2026 | 1.879B |
| September 16, 2026 | 1.777B |
| September 15, 2026 | 1.784B |
| September 14, 2026 | 1.833B |
| September 11, 2026 | 1.879B |
| September 10, 2026 | 1.952B |
| September 09, 2026 | 2.036B |
| September 08, 2026 | 2.068B |
| September 04, 2026 | 2.138B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Pfizer Inc. | 213.37B |
| Johnson & Johnson | 715.26B |
| Merck & Co., Inc. | 408.57B |
| Bristol Myers Squibb Co. | 161.88B |
| ANI Pharmaceuticals, Inc. | 1.807B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -41.90M |
| Revenue (Quarterly) | 44.95M |
| Total Expenses (Quarterly) | 86.85M |
| EPS Diluted (Quarterly) | -0.1191 |
| Gross Profit Margin (Quarterly) | 72.18% |
| Profit Margin (Quarterly) | -93.21% |
| Earnings Yield | -9.81% |
| Normalized Earnings Yield | -9.404 |